**Table S1:** Relationship between targets, ligands and their concentration.

|  |  |  |
| --- | --- | --- |
| **Targets** | **Ligands** | **Concentration** |
| mAChRs | atropine (AT) | 10 nM |
| nAChRs | mecamylamine (MM) | 10 nM |
| M1 mAChR | pirenzepine (Pir) | 10 nM |
| M2 mAChR | Methoctramine (Met) | 10 nM |
| M3 mAChR | 4-diphenylacetoxy-N-methyl-piperidine (Damp) | 10 nM |
| M4 mAChR | tropicamide (Trop) | 10 nM |
| M5 mAChR | xanomeline (Xan) | 10 nM |
| α7 nAChR | methyllycaconitine (MLA) | 10 nM |
| α9 nAChR | luteolin (Lut) | 10 nM |
| phospholipase C (PLC) | 2-nitro-4-carboxyphenyl N,N-diphenyl carbamate (NCDC) | 1 μM |
| protein kinase C (PKC) | Staurosporine (Stau) | 1 μM |
| Ras | S-trans,trans-farnesylthiosalicylic acid (FTS) | 1 μM |
| mitogen-activated protein kinase kinase (MEK) | PD098059 (PD) | 10 μM |
| extracellular signal-regulated kinases (ERK) 1/2 | U126 | 10 μM |
| IKKβ | IMD354 (IMD) | 5 μM |
| nNOS | N-[(4S)-4-amino-5-[(2-aminoethyl](amino]pentyl]-N′-nitroguanidine Tris (4S-AEPN) | 5 μM |
| iNOS | aminoguanidine (AG) | 1 mM |
| eNOS | L-N5-(1-iminoethyl) ornithine hydrochloride (L-NIO) | 10 μM |
| NOS | NGmonomethyl-L arginine (l-nmma) | 100 μM |
|  | DMSO (vehicle) | 0.05 % |